No Data
No Data
SAb Biotherapeutics Rebrands as SAB BIO
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte
Express News | SAB Bio Confirms 2024 Fiscal Outlook
Express News | SAB Bio's CFO Michael King to Depart
Express News | SAB Biotherapeutics Announces Departure of Chief Financial Officer
Express News | FDA Provides Clearance to Ind Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
No Data